Global CAR T Cell Therapy Market

Global CAR T Cell Therapy Market, By Targeted Antigen,
Therapeutic Application, and Geography - Trends,
Analysis and Forecast till 2028
In the recent past, cancer therapy such as targeted immunotherapies that includes CAR-T cell
therapies is been preferred over surgery, chemotherapy, and radiation. These target cancer cells
and strengthen the patient’s immune system against the tumor. CAR-T cell therapy is a type of
treatment in which T-cells derived from patient’s blood are modified in laboratory with the
addition of a special protein receptor on the T-cells that attack cancer cells. This special
receptor is known as Chimeric Antigen Receptor (CAR) that binds to specific protein on
patient’s cancer cells. Millions of CAR-T cells are grown in the laboratory and then
administered in the patients through infusion. These cells bind to the infected cancer cells and
have the ability to kill them thereby leading to curing of the cancer. Masking of cancer cells
from immune cells can be combated by the incorporation of immune checkpoint inhibitors in
body which can detect and inhibit cancer cells. This innovative approach of using the body’s
immune cells to target cancer causing cells has been successful used in the treatment of
pediatric relapsed acute lymphoblastic leukemia, refractory non-Hodgkin lymphoma, and other
cancers.
For In depth Information Get Sample Copy of this Report @
https://www.coherentmarketinsights.com/insight/request-sample/102
The global CAR-T Cell therapy market is estimated to be valued at US$ 295.1 million in 2018
and is expected to witness a CAGR of 32.5 % over the forecast period (2018 – 2028).
Market Dynamics
CAR-T cell therapy is expected to be an important development in cancer treatment and
therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading
to high demand for its treatment. According to the World Cancer Research Fund International
(WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it
is projected that by 2035, around 24 million cancer cases would be observed worldwide.
Moreover, introduction of new therapies into the market is further expected to bolster growth
of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug
Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based
gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However,
risks of side effects resulting in various neurological disorders is expected to hinder growth of
the global CAR-T cell therapy market.
Report includes chapters which deeply display the following deliverable about industry :
• Global CAR T Cell Therapy Market Research Objective and Assumption
• Global CAR T Cell Therapy Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Global CAR T Cell Therapy Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Global CAR T Cell Therapy Market, By Regions
• Global CAR T Cell Therapy Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Global CAR T Cell Therapy Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Global CAR T Cell Therapy Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Global CAR T Cell Therapy Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Increasing incidence of cancer and rising number of patients showing response failure to
alternative treatments is expected to foster growth of the global CAR-T cell therapy market.
Rising number of adults and children developing cancer is expected to lead to high demand for
an effective and reliable therapeutic treatment approach for improvement of quality of patient’s
lives. The Cancer Research UK reported that over 14.1 million cancer cases occurred in 2012
across the world. Moreover, according to the Leukemia and Lymphoma Society of Canada,
around 22,340 people in Canada were diagnosed with some form of blood cancer, of which
9,000 cases were lymphoma.
Ask For Discount Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/102
Moreover, development of new and effective therapy options to cure symptoms of the disease is
also a vital factor contributing to growth of CAR-T cell therapy market. In 2017, the U.S. Food
and Drug Administration approved two CAR-T cell therapies Kymriah and Yescarta for children
and adult lymphoblastic leukemia and advanced lymphoma in adults, respectively. This is
expected to aid in growth of the market over the forecast period.
Market players are engaged in developing and launching innovative products and adopt merger
and acquisition strategies to retain position in the global CAR-T cell therapy market
Key players in the market are engaged in extensive research and development to launch new
targeted cell therapies in the market. For instance, the University of Texas MD Anderson Cancer
Center, Houston is conducting phase 1 clinical trial studies of central memory–derived CD19
CAR T–cell therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma. Moreover,
key players are focusing on strategic merger and acquisition to enhance their share in the
global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with
Allogene, to develop an investigational CAR-T cell therapy for treating cancer.
Key players operating in the global CAR-T cell therapy market include Novartis International
AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird
Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora
Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen
Therapeutics, Ltd., and others.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

In the recent past, cancer therapy such as targeted immunotherapies that includes CAR-T cell therapies is been preferred over surgery, chemotherapy, and radiation.

Download Report